Alignment Healthcare, Inc. (ALHC)
NASDAQHealth CareMedical - Healthcare PlansSnapshot 2026-09-04
$13.54-0.07%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Healthcare PlansSnapshot 2026-09-04
Intact: The reason to own it still holds.
Alignment Healthcare grows revenue about 33% next year to $5.2 billion. It offers personalized healthcare to seniors, a growing market. Leadership changes strengthen its strategy. The stock has gained nearly 60% in 3 months.
The stock is expensive with a PE of 77.6 versus peers at 30.6. Policy risks could hurt growth. Insider selling raises concerns about regulatory challenges.
The price is about 27% above our fair value near $19 and 8% below the Street median. Analysts expect 33% revenue growth, which the market largely prices in. Our view is slightly more cautious than the Street.
Breaks if: Significant leadership departures or strategy reversals
Breaks if: EPS falls below $0.40 in FY26
Material negative regulatory rulings or reimbursement cuts
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making but has demonstrated strong revenue growth and raised guidance, indicating potential for future profitability.
The market appears to have priced in a justified valuation, with ALHC trading at a premium compared to its peers. However, there is an expectations gap, suggesting that the market may not fully account for potential risks in the near term.
Management is focused on growing Medicare Advantage membership and increasing revenue, both of which have shown strong growth recently. However, there are mixed signals regarding the improvement of adjusted gross profit and adjusted EBITDA, which could impact future performance.
The long-term thesis hinges on the ability of ALHC to maintain its growth trajectory while navigating near-term risks, such as potential guidance cuts or economic downturns. Additionally, the performance of sector bellwethers like UNH, CVS, and ELV will be crucial in determining the overall momentum in the healthcare sector.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no current threats to the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Revenue falls below $4.9B in FY26
Overall, ALHC's strong recent results provide a solid foundation, but elevated risks and mixed management priorities warrant careful observation. Not investment advice.